Observational study finds longer overall survival with trifluridine–tipiracil plus bevacizumab in mCRC, suggesting potential treatment benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nusrat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: